(Q38182355)

30 August 2017

title

Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies (English)

1 reference

30 August 2017

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469030%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

D Nagel

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469030%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

M Vincendeau

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469030%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

A C Eitelhuber

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469030%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

English

0 references

publication date

27 January 2014

1 reference

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469030%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469030%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469030%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

5655-5665

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469030%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2013.565

2 June 2020

exact match

0 references

cites work

Molecular basis of NF-κB signaling

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

The NF-kappaB family of transcription factors and its regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Regulation of NF-κB by ubiquitination and degradation of the IκBs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

NF-κB, the first quarter-century: remarkable progress and outstanding questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

IkappaB kinase complexes: gateways to NF-kappaB activation and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Shared principles in NF-kappaB signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Non-canonical NF-κB signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

B cell receptor signal strength determines B cell fate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Analysis of CARMA1/BCL10/MALT1 expression in Reed-Sternberg cells of classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Frequent inactivation of A20 in B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Regulation of NF-κB by deubiquitinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Aberrant NF-kappaB2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

MALT1 protease: a new therapeutic target in B lymphoma and beyond?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

MALT lymphoma: from morphology to molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

MALT lymphoma: many roads lead to nuclear factor-κb activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

The proteolytic activity of the paracaspase MALT1 is key in T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Malt1 and cIAP2-Malt1 as effectors of NF-kappaB activation: kissing cousins or distant relatives?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Selective Expansion of Marginal Zone B Cells in Eμ-API2-MALT1 Mice Is Linked to Enhanced IκB Kinase γ Polyubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Non-canonical NF-κB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

A dual role for the API2 moiety in API2-MALT1-dependent NF-kappaB activation: heterotypic oligomerization and TRAF2 recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

TRAF2-binding BIR1 domain of c-IAP2/MALT1 fusion protein is essential for activation of NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

The biology of human lymphoid malignancies revealed by gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Stromal gene signatures in large-B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Prostate stem cell antigen is overexpressed in prostate cancer metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

A loss-of-function RNA interference screen for molecular targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Genetic heterogeneity of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Tyrosine kinases and their substrates in B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Visualization of Syk-antigen receptor interactions using green fluorescent protein: differential roles for Syk and Lyn in the regulation of receptor capping and internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Oncogenic CARD11 mutations in human diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Analysis of the coding genome of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Oncogenic CARD11 Mutations Induce Hyperactive Signaling by Disrupting Autoinhibition by the PKC-Responsive Inhibitory Domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Human lymphoma mutations reveal CARD11 as the switch between self-antigen-induced B cell death or proliferation and autoantibody production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Congenital B cell lymphocytosis explained by novel germline CARD11 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

The protease activity of the paracaspase MALT1 is controlled by monoubiquitination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Oncogenically active MYD88 mutations in human lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Frequent engagement of RelB activation is critical for cell survival in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

BCMA is essential for the survival of long-lived bone marrow plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Classical and/or alternative NF-kappaB pathway activation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

NF-kappa B p100 (Lyt-10) is a component of H2TF1 and can function as an I kappa B-like molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

A fourth IkappaB protein within the NF-kappaB signaling module

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Proteasome inhibitors in multiple myeloma: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

NF-kappaB in the pathogenesis and treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Inhibiting NF-κB-inducing kinase (NIK): discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

NF-kappaB inducing kinase (NIK) inhibitors: identification of new scaffolds using virtual screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Frequent occurrence of deletions in primary mediastinal B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Mutational analysis of the IkappaBalpha gene in activated B cell-like diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Prognostic significance of EBV latent membrane protein 1 expression in lymphomas: evidence from 15 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565

Gains ofREL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.565